InSilicoTrials has entered a collaborative partnership with Axoltis Pharma to advance therapeutic solutions for neurological disorders.

The firms will develop disease-modifying drugs to treat patients with neurodegenerative and traumatic neurologic impairments.

The partnership aims to enhance the clinical development plan of Axoltis’ drug candidate, NX210c, a 12-amino acid peptide derived from SCO-spondin. 

This collaboration’s key focus will be to use InSilicoTrials’ platform and leverage its InSilicoNEURO suite, which consists of diverse mechanistic central nervous system (CNS) models.

Models within InSilicoNEURO will be used to evaluate the potential of Axoltis’ drug candidate on virtual patients with conditions, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis.

Mechanistic CNS models simulate the physiological and pathological aspects of CNS disorders, offering a better understanding of disease mechanisms and possible therapeutic interventions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Axoltis CEO Yann Godfrin stated: “Integrating their industry-leading AI and computational modelling solutions in the development plan of our promising disease-modifying drug will allow us to address the pressing challenges faced by individuals suffering from neurological disorders.”

The companies will leverage InSilicoTrials’ digital platform and use data from Phase Ib clinical trials and the preclinical package to analyse the connection between NX210c dosing regimens, blood-brain barrier repair, neurological function, biomarker concentrations, clinical efficacy and safety outcomes.

This analysis will be achieved through computational modelling and simulation, and artificial intelligence techniques.

InSilicoTrials CEO Luca Emili stated: “Together, we aim to unlock new insights and develop groundbreaking treatments that will positively impact the lives of patients with neurologic impairments worldwide.”